Novartis investigational compound LBH589 significantly extended time without disease progression in

Novartis announced that results of a Phase III trial of the investigational compound LBH589 (panobinostat) in combination with bortezomib and dexamethasone, met the primary endpoint of significantly extending progression-free survival (PFS) in patients with relapsed or relapsed and refractory multiple myeloma when compared to bortezomib plus dexamethasone alone.

Multiple myeloma affects approximately 1 to 5 in every 100,000 people worldwide each year. The five year survival-rate for patients with the disease is about 44%.

LBH589 showed significant clinical benefit bringing it a step closer to becoming the first in its class of anticancer agents to be available to patients with multiple myeloma. As a pan-deacetylase (pan-DAC) inhibitor, LBH589 works by blocking a key cancer cell enzyme which ultimately leads to cellular stress and death of these cells.

Prior data demonstrated that oral LBH589, when combined with bortezomib and dexamethasone, recaptures responses in heavily pretreated and bortezomib-refractory multiple myeloma patients, thereby providing these patients with a potential new option after failing prior standard treatments. The compound's possible benefits and risks are also being explored in additional hematologic malignancies through ongoing clinical trials.

The PANobinostatORAl in Multiple MyelomA (PANORAMA) clinical trial program is evaluating LBH589 in patients with relapsed or relapsed and refractory multiple myeloma.

The PANORAMA-1 clinical trial is a Phase III randomized, double blind, placebo controlled, multicenter global registration trial to evaluate Lbh589 in combination with bortezomib and dexamethasone against bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma. The primary endpoint of the trial was progression-free survival (PFS) and the key secondary endpoint is overall survival (OS). Other secondary endpoints include overall response rate, duration of response and safety.

To enter a cell, a gold nanoparticle interacts with the cell membrane in a specific way. Because of the hydrophobic and hydrophilic nature of the lipid bilayer, and because of imperfections in the membrane, there is often some open space in the membranes. And these ultimately play into a particle's ability to make it through, leaving space in the curved areas of the cell for easier access. This discovery could give engineers a leg up in designing new gold particles with a more targeted approach. For instance, perhaps new surface ligands for nanoparticles could be engineered to have improved affinity for both surface groups and lipid tails.

Numerologist Warda is hooked on OG-L002 fishing, collecting. And lastly her encouragement comes from socializing along with her companions.